Development of a Dose-Adjusted Polygenic Risk Model for Anthracycline-Induced Cardiotoxicity

These findings suggest that the SLC28A3 variant imparts more significant protection for patients receiving higher anthracycline doses, whereas the UGT1A6 and RARG risk variants significantly increased the risk of cardiotoxicity at low anthracycline doses.